This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Subscribe To Our Newsletter & Stay Updated
